Visitor Ratings
Google PR
Visitor Ratings
Google PR
Visitor Ratings
Google PR New Sanofi CEO Expected to Map Fresh Course on Developing Drugs Wall Street Journal - One example: the obesity pill Acomplia, which Sanofi continued to develop years after signs emerged that the drug had negative psychological side effects. ... Viehbacher, Passed Over at Glaxo, Takes Sanofi Reins (Update1) Viehbacher’s First Day On The Job At Sanofi Welvista Announces Partnering with sanofi-aventis US to Provide ... |
Anti-obesity agent Acomplia is withdrawn Healthcare Republic - The marketing authorisation for Acomplia (rimonabant) has been suspended after a European Medicines Agency (EMEA) review. The EMEA's Committee for Medicinal ... |
![]() That Happened! | Sanofi Ends All Human Trials of Acomplia Obesity Drug (Update1) Bloomberg - 5 (Bloomberg) -- Sanofi-Aventis SA, France's largest drugmaker, is halting all human trials of the Acomplia obesity medicine after health authorities in a ... UPDATE 1-Sanofi scraps all trials of Acomplia RIP, Acomplia Diet Drug Acomplia (Rimonabant) Reaches End of Road |